The neuropeptide y Y1 receptor knockdown modulates activator protein 1-involved feeding behavior in amphetamine-treated rats

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Hsieh, Yih Shou ^a   Chen, Pei Ni ^a   Yu, Ching Han ^a   Liao, Jiuan Miaw ^a   Kuo, Dong Yih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AP 1; Appetite; c Fos; c Jun; Hypothalamus; NPY Y1 receptor

Indexed keywords

AMPHETAMINE; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y Y1 RECEPTOR; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; FEEDING BEHAVIOR; FOOD INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

RATTUS;

ALPHA-METHYLTYROSINE; AMPHETAMINE; ANIMALS; APPETITE; ARGININE; CHROMATIN IMMUNOPRECIPITATION; FEEDING BEHAVIOR; GENE KNOCKDOWN TECHNIQUES; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPEPTIDE Y; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, WISTAR; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, NEUROPEPTIDE Y; TRANSCRIPTION FACTOR AP-1;

EID: 84887397321     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-46     Document Type: Article

References (70)

1. Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Tata DA, Yamamoto BK, Addiction 2007 102 49 60 17493053 (Pubitemid 46328208)
2. Brain injury associated with widely abused amphetamines: neuroinflammation, neurogenesis and blood-brain barrier. Silva AP, Martins T, Baptista S, Gonçalves J, Agasse F, Malva JO, Curr Drug Abuse Rev 2010 3 239 254 10.2174/1874473711003040239 21208167
3. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? Hodgkins P, Shaw M, McCarthy S, Sallee FR, CNS Drugs 2012 26 245 268 10.2165/11599630-000000000-00000 22329564
4. L-amphetamine improves memory in MS patients with objective memory impairment. Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J, Mult Scler 2011 17 1141 1145 10.1177/1352458511404585 21561956
5. Cocaine-and amphetamine-regulated transcript modulates peripheral immunity and protects against brain injury in experimental stroke. Chang L, Chen Y, Li J, Liu Z, Wang Z, Chen J, Cao W, Xu Y, Brain Behav Immun 2011 25 260 269 10.1016/j.bbi.2010.09.017 20869431
6. Use of psychostimulants in patients with dementia. Dolder CR, Davis LN, McKinsey J, Ann Pharmacother 2010 44 1624 1632 10.1345/aph.1P341 20736422
7. Amphetamine derivatives and obesity. Ricca V, Castellini G, Mannucci E, Monami M, Ravaldi C, Gorini Amedei S, Lo Sauro C, Rotella CM, Faravelli C, Appetite 2009 52 405 409 10.1016/j.appet.2008.11.013 19103239
8. NF-kappaB knockdown can modulate amphetamine-mediated feeding response. Kuo DY, Chen PN, Kuo MH, Chen CH, Hsieh YS, Chu SC, Neuropharmacology 2012 62 1684 1694 10.1016/j.neuropharm.2011.11.014 22182781
9. Role of cerebral dopamine but not plasma insulin, leptin and glucocorticoid in the development of tolerance to the anorectic effect of amphetamine. Kuo DY, Cheng JT, Neurosci Res 2002 44 63 69 10.1016/S0168-0102(02) 00086-X 12204294 (Pubitemid 36158704)
10. Knocking down the transcript of protein kinase C-lambda modulates hypothalamic glutathione peroxidase, melanocortin receptor and neuropeptide Y gene expression in amphetamine-treated rats. Hsieh YS, Yang SF, Chen PN, Chu SC, Chen CH, Kuo DY, J Psychopharmacol 2011 25 982 994 10.1177/0269881110376692 20817751
11. Role of reactive oxygen species-related enzymes in neuropeptide Y and proopiomelanocortin-mediated appetite control: a study using atypical protein kinase C knockdown. Kuo DY, Chen PN, Yang SF, Chu SC, Chen CH, Kuo MS, Yu CH, Hsieh YS, Antioxid Redox Signalings 2011 15 2147 2159 10.1089/ars.2010.3738
12. The role of NPY in hypothalamic mediated food intake. Mercer RE, Chee MJ, Colmers WF, Front Neuroendocrinol 2011 32 398 415 Review 10.1016/j.yfrne.2011. 06.001 21726573
13. Neuropeptide Y and peptide YY: important regulators of energy metabolism. Nguyen AD, Herzog H, Sainsbury A, Curr Opin Endocrinol Diabetes Obes 2011 18 56 60 10.1097/MED.0b013e3283422f0a 21157324
14. A possible role of neuropeptide Y in depression and stress. Morales-Medina JC, Dumont Y, Quirion R, Brain Res 2010 1314 194 205 19782662
15. Comparison of the activation of somatostatin- and neuropeptide Y-containing neuronal populations of the rat amygdala following two different anxiogenic stressors. Butler RK, White LC, Frederick-Duus D, Kaigler KF, Fadel JR, Wilson MA, Exp Neurol 2012 238 52 63 10.1016/j.expneurol.2012.08.002 22917777
16. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Michel MC, Beck-Sickinger A, Cox HXVI, et al. Pharmacol Rev 1998 50 143 150 9549761 (Pubitemid 28158845)
17. A receptor subtype involved in neuropeptide-Y-induced food intake. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, et al. Nature 1996 382 168 171 10.1038/382168a0 8700207 (Pubitemid 26242883)
18. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, Kanatani A, Eur J Pharmacol 2009 615 113 117 10.1016/j.ejphar.2009.05.018 19482021
19. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptordeficient mice. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M, Proc Natl Acad Sci USA 1998 95 15659 15664 10.1073/pnas.95.26.15659 9861026 (Pubitemid 29018756)
20. Feeding behavior and gene expression of appetite-related neuropeptides in mice lacking for neuropeptide Y Y5 receptor subclass. Higuchi H, Niki T, Shiiya T, World J Gastroenterol 2008 14 6312 6317 10.3748/wjg.14.6312 19009645
21. Involvement of neuropeptide Y Y1 receptor in the regulation of amphetamine-mediated appetite suppression. Kuo DY, Chen PN, Yu CH, Kuo MH, Hsieh YS, Chu SC, Neuropharmacology 2012 63 842 850 10.1016/j.neuropharm.2012.06.018 22732442
22. The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase of oxidative stress and appetite suppression. Hsieh YS, Chen PN, Kuo MH, Kuo DY, NeuroMolecular Med 2013 15 159 168 10.1007/s12017-012-8206-x 23179670
23. Drugs of abuse and brain gene expression. Torres G, Horowitz JM, Psychosom Med 1999 61 630 650 10511013 (Pubitemid 29455086)
24. Stress and amphetamine induce Fos expression in medial prefrontal cortex neurons containing glucocorticoid receptors. Ostrander MM, Richtand NM, Herman JP, Brain Res 2003 990 209 214 10.1016/j.brainres.2003.07.001 14568346 (Pubitemid 37244077)
25. Mice with partial deficiency of c-Jun show attenuation of methamphetamine-induced neuronal apoptosis. Deng X, Jayanthi S, Ladenheim B, Krasnova IN, Cadet JL, Mol Pharmacol 2002 62 993 1000 10.1124/mol.62.5.993 12391261 (Pubitemid 35222490)
26. Activations of c-fos/c-jun signaling are involved in the modulation of hypothalamic superoxide dismutase (SOD) and neuropeptide Y (NPY) gene expression in amphetamine-mediated appetite suppression. Hsieh YS, Yang SF, Chiou HL, Kuo DY, Toxicol Appl Pharmacol 2006 212 99 109 10.1016/j.taap.2005.07.006 16084549
27. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Angel P, Karin M, Biochim Biophys Acta 1991 1072 129 157 1751545 (Pubitemid 121007534)
28. Activator protein-1 binding activities in discrete regions of rat brain after acute and chronic administration of methamphetamine. Ishihara T, Akiyama K, Kashihara K, Ujike H, Hamamura T, Okada S, Kuroda S, J Neurochem 1996 67 708 716 8764599 (Pubitemid 26255668)
29. Enhancement of AP-1 DNA-binding activity during amphetamine- and phencyclidine-mediated behaviour in rats. Milanovic D, Pesic V, Rakic L, Kanazir S, Ruzdijic S, Neuropharmacology 2006 50 924 933 10.1016/j.neuropharm.2006.01. 011 16678866 (Pubitemid 43794902)
30. Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. Yuan J, Callahan BT, McCann UD, Ricaurte GA, J Neurochem 2001 77 1338 1347 10.1046/j.1471-4159.2001.00339.x 11389185 (Pubitemid 32523687)
31. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Zhang M, Creese I, Neurosci Lett 1993 161 223 226 10.1016/0304-3940(93)90299-Z 7903803 (Pubitemid 23314873)
32. Current status of antisense DNA methods in behavioral studies. Ogawa S, d Pfaff DW, Chem Senses 1998 23 249 255 10.1093/chemse/23.2.249 9589170 (Pubitemid 28159969)
33. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP 3226. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, et al. Eur J Pharmacol 1994 271 11 R13 10.1016/0014-2999(94)90822-2 7705422
34. Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. O'Shea D, Morgan DG, Meeran K, Edwards CM, Turton MD, Choi S, et al. Endocrinology 1997 138 196 202 10.1210/en.138.1.196 8977404 (Pubitemid 27009424)
35. Paxinos G, Watson C, The rat brain in stereotaxic coordinates Sydney, Australia: Academic Press 2 1986
36. Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. Ritter RC, Slusser PG, Stone S, Science 1981 213 451 452 10.1126/science.6264602 6264602
37. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Heilig M, Regul Pept 1995 59 201 205 10.1016/0167-0115(95)00103-I 8584755
38. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. Widnell KL, Self DW, Lane SB, Russell DS, Vaidya V, Miserendino MJD, et al. J Pharmacol Exp Ther 1996 276 306 315 8558448 (Pubitemid 26150971)
39. Centrally administered oligodeoxynucleotides in rats: occurrence of non-specific effects. Schöbitz B, Pezeshki G, Probst JC, Reul JM, Skutella T, Stöhr T, Holsboer F, Spanagel R, Eur J Pharmacol 1997 331 97 107 10.1016/S0014-2999(97)01014-5 9274967 (Pubitemid 27331437)
40. Amphetamine-evoked changes of oxidative stress and neuropeptide Y gene expression in hypothalamus: regulation by the protein kinase C-delta signaling. Kuo DY, Yang SF, Chu SC, Chen CH, Hsieh YS, Chemicals-Biological Interactions 2009 180 193 201 10.1016/j.cbi.2009.03.013
41. Dioscorea nipponica Makino inhibits migration and invasion of human oral cancer HSC-3 cells by transcriptional inhibition of matrix metalloproteinase-2 through modulation of CREB and AP-1 activity. Chien MH, Ying TH, Hsieh YS, Chang YC, Yeh CM, et al. Food Chem Toxicol 2012 50 558 566 10.1016/j.fct.2011.12.016 22210353
42. Mulberry anthocyanins, cyanidin 3-rutinoside and cyaniding 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Chen PN, Chu SC, Chiou HL, Kuo WH, Chiang CL, Hsieh YS, Cancer Lett 2006 235 248 259 10.1016/j.canlet.2005.04.033 15975709
43. Intracerebral administration of protein kinase A (PKA) or c-AMP response element binding protein (CREB) antisense oligonucleiotide can modulate amphetamine-mediated appetite suppression in free-moving rats. Hsieh YS, Yang SF, Kuo DY, Ame J Physiol-Endocrinol Metab 2007 292 123 131
44. Inhibition of neuropeptide Y (NPY)-induced feeding and c-Fos response in magnocellular paraventricular nucleus by a NPY receptor antagonist: a site of NPY action. Yokosuka M, Kalra PS, Kalra SP, Endocrinology 1999 140 4494 4500 10.1210/en.140.10.4494 10499503 (Pubitemid 30666113)
45. Fuel utilization by hypothalamic neurons: roles for ROS. Horvath TL, Andrews ZB, Diano S, Trends Endocrinol Metab 2009 20 78 87 10.1016/j.tem.2008. 10.003 19084428
46. Neuropeptide Y suppresses anorexigenic output from the ventromedial nucleus of the hypothalamus. Chee MJ, Myers MG Jr, Price CJ, Colmers WF, J Neurosci 2010 30 3380 3390 10.1523/JNEUROSCI.4031-09.2010 20203197
47. Inhibiting neuropeptide Y Y1 receptor modulates melanocortin receptor- and NFkB-mediated feeding behavior in phenylpropanolamine-treated rats. Hsieh YH, Chen PN, Yu CH, Liao JM, Kuo DY, Horm Behav 2013 64 95 102 10.1016/j.yhbeh.2013.05.005 23707533
48. Physiology and gene regulation of the brain NPY Y1 receptor. Eva C, Serra M, Mele P, Panzica G, Oberto A, Front Neuroendocrinol 2006 27 308 339 10.1016/j.yfrne.2006.07.002 16989896 (Pubitemid 44548041)
49. NPY receptors as potential targets for anti-obesity drug development. Yulyaningsih E, Zhang L, Herzog H, Sainsbury A, Br J Pharmacol 2011 163 1170 1202 10.1111/j.1476-5381.2011.01363.x 21545413
50. Transcriptional interruption of cAMP response element binding protein modulates superoxide dismutase and neuropeptide Y-mediated feeding behavior in freely moving rats. Hsieh YS, Yang SF, Chu SC, Ho YJ, Kuo CS, Kuo DY, J Neurochem 2008 105 1438 1449 10.1111/j.1471-4159.2008.05246.x 18221372 (Pubitemid 351590803)
51. Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element binding protein in phenylpropanolamine-treated rats. Hsieh YS, Chen PN, Kuo MS, Kuo DY, Archi Toxicol 2013 87 469 479 10.1007/s00204-012-0947-7
52. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Cohen H, Liu T, Kozlovsky N, Kaplan Z, Zohar J, Mathé AA, Neuropsychopharmacology 2012 37 350 363 10.1038/npp.2011.230 21976046
53. Re-exposure and environmental enrichment reveal NPY-Y1 as a possible target for post-traumatic stress disorder. Hendriksen H, Bink DI, Daniels EG, Pandit R, Piriou C, Slieker R, Westphal KG, Olivier B, Oosting RS, Neuropharmacology 2012 63 733 742 10.1016/j.neuropharm.2012.05.028 22659471
54. Increased expression of c-fos mRNA and AP-1 transcription factors after cortical impact injury in rats. Yang K, Mu XS, Xue JJ, Whitson J, Salminen A, Dixon CE, Liu PK, Hayes RL, Brain Res 1994 664 141 147 10.1016/0006-8993(94) 91964-X 7895023 (Pubitemid 24347606)
55. AP-1 transcription factor complexes in CNS disorders and development. Pennypacker KR, J Fla Med Assoc 1995 82 551 554 7561734
56. AP-1 DNA-binding activation by methamphetamine involves oxidative stress. Sheng P, Wang XB, Ladenheim B, Epstein C, Cadet JL, Synapse 1996 24 213 217 10.1002/(SICI)1098-2396(199611)24:3<213::AID-SYN2>3.0.CO;2-H 8923660 (Pubitemid 26386831)
57. Chronic administration of glucocorticoids directly upregulates prepro-neuropeptide Y and Y1-receptor mRNA levels in the arcuate nucleus of the rat. Larsen PJ, Jessop DS, Chowdrey HS, Lightman SL, Mikkelsen JD, J Neuroendocrinol 1994 6 153 159 10.1111/j.1365-2826.1994.tb00566.x 8049712 (Pubitemid 24179756)
58. Cross-talk between glucocorticoid receptor and AP-1. Herrlich P, Oncogene 2001 20 2465 2475 10.1038/sj.onc.1204388 11402341 (Pubitemid 32531303)
59. Effects of age and dexamethasone treatment on glucocorticoid response element and activating protein-1 binding activity in rat brain. Terzic N, Vujcic M, Ristic-Fira A, Krstic-Demonacos M, Milanovic D, Kanazir DT, Ruzdijic S, J Gerontol A Biol Sci Med Sci 2003 58 297 303 10.1093/gerona/58.4.B297 12663692 (Pubitemid 36397046)
60. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Singewald N, Salchner P, Sharp T, Biol Psychiatry 2003 53 275 283 10.1016/S0006-3223(02)01574-3 12586446 (Pubitemid 36175541)
61. Evidence for a role of inhibition of orexinergic neurons in the anxiolytic and sedative effects of diazepam: A c-Fos study. Panhelainen AE, Korpi ER, Pharmacol Biochem Behav 2012 101 115 124 10.1016/j.pbb.2011.12.011 22210490
62. Distribution of dopamine D(2)-like receptors in the rat amygdala and their role in the modulation of unconditioned fear and anxiety. Perez de la Mora M, Gallegos-Cari A, Crespo-Ramirez M, Marcellino D, Hansson AC, Fuxe K, Neuroscience 2012 201 252 266 22100273
63. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: structural and functional analysis. de la Mora MP, Gallegos-Cari A, Arizmendi-García Y, Marcellino D, Fuxe K, Prog Neurobiol 2010 90 198 216 10.1016/j.pneurobio.2009.10.010 19853006
64. Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test. Biala G, Kruk M, Budzynska B, J Physiol Pharmacol 2009 60 113 122
65. Anxiogenic-like activity of 3,4-methylenedioxy-methamphetamine ("Ecstasy") in the social interaction test is accompanied by an increase of c-fos expression in mice amygdala. Navarro JF, Rivera A, Maldonado E, Cavas M, de la Calle A, Prog Neuropsychopharmacol Biol Psychiatry 2004 28 249 254 10.1016/j.pnpbp.2003.10.016 14751419 (Pubitemid 38130129)
66. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Sainsbury A, Schwarzer C, Couzens M, Herzog H, Diabetes 2002 51 3420 3427 10.2337/diabetes.51.12.3420 12453895 (Pubitemid 35403445)
67. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Naveilhan P, Hassani H, Canals JM, Ekstrand AJ, Larefalk A, Chhajlani V, et al. Nat Med 1999 5 1188 1193 10.1038/13514 10502824 (Pubitemid 29474425)
68. Stress-induced changes in adrenal neuropeptide Y expression are regulated by a negative feedback loop. Wang Q, Whim MD, J Neurochem 2013 125 16 25 10.1111/jnc.12150 23311866
69. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. Brothers SP, Wahlestedt C, EMBO Mol Med 2010 2 429 439 10.1002/emmm.201000100 20972986
70. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. MacNeil DJ, Curr Top Med Chem 2007 7 1721 1733 10.2174/156802607782341028 17979781 (Pubitemid 350131009)